StockData

Lipocine vs Ovid Therapeutics

LPCN and OVID side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LPCN and OVID compare

Ovid Therapeutics is the larger company, worth 33 times as much as Lipocine ($434M against $13.2M).

Lipocine grew revenue faster over the last twelve months (−62.7% versus −76.2% for Ovid Therapeutics).

Lipocine keeps more of each dollar of sales as profit, with a net margin of −755% compared with −2179% at Ovid Therapeutics.

Ovid Therapeutics scores higher on the StockData Score (10 against 9 for Lipocine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLPCNOVID
Size and price
Market cap$13.2M$434M
Share price$1.60$2.22
Change, 1 year−44.3%70.1%
Change, 5 years−91.7%−31.9%
Beta (5Y)−0.381.34
Employees1423
StockData Score
Total score910 (better)
Valuation score3 (better)1
Growth score11
Performance score02 (better)
Health score56 (better)
Dividend score00
Valuation
P/S8.4× (better)274×
P/B0.6× (better)2.1×
Fair value$2.64–
Margin of safety39.3%–
Growth
Revenue growth (TTM)−62.7% (better)−76.2%
Revenue growth, 5Y average–−10.5%
Profitability
Operating margin−801% (better)−3687%
Net margin−755% (better)−2179%
Return on equity−60.9%−26.0% (better)
Return on invested capital–−160%
Financial health
Debt / equity0.000.00
Current ratio11.4812.39 (better)
Altman Z-score−9.439.41 (better)
Piotroski F-score14 (better)
Dividends and buybacks
Buyback yield−123%–
Shareholder yield−123%0.00% (better)
Ownership
Held by institutions36.2%75.3%
Held by insiders9.0%13.6%
Insider net buying, 12 months$596K (better)−$29.3K
Short interest, % of float4.3%10.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.